|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...4647484950515253545556...6768» |
- Zarnestra (tipifarnib) / Kura Oncology
Trial completion: Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia (clinicaltrials.gov) - Jun 2, 2013
P2, N=35, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed
- Trial termination: Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant (clinicaltrials.gov) - Jun 2, 2013
P2, N=45, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated; The study was closed early due to weak accrual on June 26, 2012.
- bortezomib / Generic mfg.
Trial termination, Combination therapy: 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Jun 2, 2013
P1, N=74, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; The study was closed early due to weak accrual on June 26, 2012. Completed --> Terminated
- |||| Sylvant (siltuximab) / Jazz
Trial completion: A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients (clinicaltrials.gov) - Jun 2, 2013
P2, N=118, Completed, Sponsor: Janssen Research & Development, LLC
Completed --> Terminated Active, not recruiting --> Completed
- sirexatamab (DKN-01) / Leap Therap
Enrollment open: A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 30, 2013
P1/2, N=20, Recruiting, Sponsor: Dekkun Corporation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Kepivance (palifermin) / SOBI, Amgen
Enrollment change: Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant (clinicaltrials.gov) - May 29, 2013
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=200 --> 0
- ||||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
New P1/2 trial: Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma (clinicaltrials.gov) - May 29, 2013
P1/2, N=55, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Promacta (eltrombopag) / Novartis
Clinical: Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Treatment (clinicaltrials.gov) - May 27, 2013
P=N/A, N=30, Recruiting, Sponsor: Shandong University
- |||||||||| Nuwiq (simoctocog alfa) / Octapharma
New P3 trial: NuPreviq: Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A (clinicaltrials.gov) - May 27, 2013
P3, N=55, Recruiting, Sponsor: Octapharma
- acetylcysteine solution / Generic mfg.
Enrollment open: NACinTTP: A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura (clinicaltrials.gov) - May 27, 2013
P0, N=3, Recruiting, Sponsor: Puget Sound Blood Center
N=200 --> 0 Not yet recruiting --> Recruiting
- Trial completion: Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors (clinicaltrials.gov) - May 27, 2013
P=N/A, N=315, Completed, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
P2 data: Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 22, 2013
P1/2, N=100, Recruiting, Sponsor: Triphase Research and Development I Corporation
Active, not recruiting --> Completed N=35 --> 100
- | marizomib (NPI-0052) / Triphase Accelerator Corporation, BMS
Trial completion: NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma (clinicaltrials.gov) - May 22, 2013
P1, N=22, Completed, Sponsor: Triphase Research and Development I Corporation
N=35 --> 100 Active, not recruiting --> Completed
- RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Enrollment open, Surgery: Fibrinogen as an Alternative to FFP in Aortic Surgery. (clinicaltrials.gov) - May 21, 2013
P4, N=20, Recruiting, Sponsor: University of Edinburgh
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Uplizna (inebilizumab-cdon) / Mitsubishi Tanabe, Amgen
Combination therapy: Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma (clinicaltrials.gov) - May 21, 2013
P0, N=15, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- melphalan / Generic mfg.
Trial completion: Phase I Study of Sequential Cord Blood Transplants (clinicaltrials.gov) - May 21, 2013
P1, N=21, Completed, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus (clinicaltrials.gov) - May 21, 2013
P2, N=32, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | melphalan / Generic mfg.
Enrollment change: SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma (clinicaltrials.gov) - May 20, 2013
P3, N=899, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed N=500 --> 899
- | alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 20, 2013
P2, N=50, Recruiting, Sponsor: Kristie Blum
N=500 --> 899 Not yet recruiting --> Recruiting
- | melphalan / Generic mfg.
Trial completion: SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma (clinicaltrials.gov) - May 20, 2013
P3, N=899, Completed, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | melphalan / Generic mfg.
Trial completion, Trial initiation date, Combination therapy: Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma (clinicaltrials.gov) - May 15, 2013
P2/3, N=4, Completed, Sponsor: University of Arkansas
Active, not recruiting --> Completed Initiation date: Nov 2003 --> Jun 2004 | Recruiting --> Completed
- melphalan / Generic mfg.
Enrollment change, Combination therapy: Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma (clinicaltrials.gov) - May 15, 2013
P2/3, N=4, Completed, Sponsor: University of Arkansas
Initiation date: Nov 2003 --> Jun 2004 | Recruiting --> Completed N=100 --> 4
- melphalan / Generic mfg.
Trial completion, Combination therapy: Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma (clinicaltrials.gov) - May 15, 2013
P2/3, N=4, Completed, Sponsor: University of Arkansas
N=100 --> 4 Recruiting --> Completed
- Beleodaq (belinostat) / Aurobindo, Assertio
Trial termination, Combination therapy, Metastases: PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma (clinicaltrials.gov) - May 14, 2013
P1, N=36, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Completed --> Terminated
- RG4733 / Roche
Trial initiation date, Combination therapy: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - May 14, 2013
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated Initiation date: Nov 2009 --> Jun 2010
- RG4733 / Roche
Enrollment closed, Combination therapy: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - May 14, 2013
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2009 --> Jun 2010 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed: Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma (clinicaltrials.gov) - May 14, 2013
P2, N=39, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg., dasatinib / Generic mfg.
Trial completion, Combination therapy: Dasatinib in Combination With Revlimid (and Dexamethasone) (clinicaltrials.gov) - May 14, 2013
P1, N=35, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Istodax (romidepsin) / Astellas, BMS
Trial completion: FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 14, 2013
P2, N=50, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- bortezomib / Generic mfg.
Trial completion, Metastases: Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction (clinicaltrials.gov) - May 14, 2013
P1, N=69, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: Evaulation of Interaction Between Herbal Products and Anticoagulants (clinicaltrials.gov) - May 12, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Completed --> Withdrawn
- Trial termination: OPTIPHASE: Individually Tailored Prophylaxis in Patients With Severe Hemophilia A (clinicaltrials.gov) - May 12, 2013
P=N/A, N=5, Terminated, Sponsor: Hospices Civils de Lyon
Completed --> Withdrawn Recruiting --> Terminated
- Enrollment change: OPTIPHASE: Individually Tailored Prophylaxis in Patients With Severe Hemophilia A (clinicaltrials.gov) - May 12, 2013
P=N/A, N=5, Terminated, Sponsor: Hospices Civils de Lyon
Recruiting --> Terminated N=60 --> 5
- Enrollment change: Evaulation of Interaction Between Herbal Products and Anticoagulants (clinicaltrials.gov) - May 12, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of California, San Francisco
N=60 --> 5 N=2000 --> 0
- | bortezomib / Generic mfg., dexamethasone injection / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial: A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - May 12, 2013
P2, N=72, Recruiting, Sponsor: Shanghai Changzheng Hospital
- | Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion: Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis (clinicaltrials.gov) - May 12, 2013
P2, N=45, Completed, Sponsor: Incyte Corporation
N=2000 --> 0 Active, not recruiting --> Completed
- | Biostate (factor VIII/von Willebrand factor) / CSL Behring
Trial initiation date: Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development (clinicaltrials.gov) - May 11, 2013
P3, N=20, Recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed Initiation date: Jun 2012 --> Dec 2012
- Clinical: Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant (clinicaltrials.gov) - May 9, 2013
P=N/A, N=7, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- | delanzomib (CEP-18770) / Teva
Trial termination: Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy (clinicaltrials.gov) - May 9, 2013
P1/2, N=62, Terminated, Sponsor: Cephalon
Initiation date: Jun 2012 --> Dec 2012 Completed --> Terminated
- Trial completion: Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant (clinicaltrials.gov) - May 9, 2013
P=N/A, N=459, Completed, Sponsor: City of Hope Medical Center
Completed --> Terminated Active, not recruiting --> Completed
- | bendamustine / Generic mfg.
New P2 trial: Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 7, 2013
P2, N=44, Recruiting, Sponsor: SymBio Pharmaceuticals
- zoledronic acid / Generic mfg.
Trial completion: Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates (clinicaltrials.gov) - May 6, 2013
P2, N=28, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Trial initiation date: High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - May 6, 2013
P2, N=451, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Initiation date: Jul 1991 --> Dec 1991
- Trial completion: Investigation of the Cylex® ImmuKnow® Assay (clinicaltrials.gov) - May 6, 2013
P=N/A, N=45, Completed, Sponsor: Indiana University School of Medicine
Initiation date: Jul 1991 --> Dec 1991 Active, not recruiting --> Completed
- Trial completion: FM 140 vs FM100 Study in Patients With Multiple Myeloma (clinicaltrials.gov) - May 6, 2013
P2, N=52, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - May 6, 2013
P2, N=451, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | armodafinil / Generic mfg.
Enrollment closed: A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma (clinicaltrials.gov) - May 5, 2013
P3, N=50, Active, not recruiting, Sponsor: Oncotherapeutics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | NovoThirteen (catridecacog) / Novo Nordisk
New P1 trial: Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers (clinicaltrials.gov) - May 5, 2013
P1, N=50, Completed, Sponsor: Novo Nordisk
- | NovoThirteen (catridecacog) / Novo Nordisk
New P1 trial: Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers (clinicaltrials.gov) - May 5, 2013
P1, N=24, Completed, Sponsor: Novo Nordisk
- linsitinib (ASP7487) / Sling Therap
Enrollment open, Combination therapy: A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma (clinicaltrials.gov) - May 5, 2013
P1/2, N=75, Recruiting, Sponsor: University Health Network, Toronto
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting